

David Preiss

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8683817/david-preiss-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

5,774
citations

25
h-index

55
g-index

55
ext. papers

6,727
ext. citations

14.3
avg, IF

5.19
L-index

#	Paper	IF	Citations
42	Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2021 ,	14.6	0
41	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. <i>Circulation</i> , 2020 , 142, 621-642	16.7	88
40	Research digest: progress in microvascular complications. <i>Lancet Diabetes and Endocrinology,the</i> , 2018 , 6, 93	18.1	2
39	Effect of Evolocumab on Lipoprotein Particles. <i>American Journal of Cardiology</i> , 2018 , 121, 308-314	3	21
38	Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. <i>Circulation</i> , 2017 , 135, 1819-1831	16.7	52
37	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 97-105	18.1	225
36	Research digest: the risks of type 2 diabetes at a young age. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 331	18.1	3
35	Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017 , 120, 1521-1527	3	29
34	Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 356-363	6.7	35
33	Research digest: cardiac biomarkers for risk prediction. <i>Lancet Diabetes and Endocrinology,the</i> , 2016 , 4, 890	18.1	2
32	Metformin Therapy and Circulating NT-proBNP Levels: The CAMERA Trial. <i>Diabetes Care</i> , 2016 , 39, e114-114.6	54.6	2
31	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016 , 39, 137-44	3.3	25
30	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. <i>European Journal of Heart Failure</i> , 2016 , 18, 1491-1498	12.3	41
29	Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing. <i>Lancet Diabetes and Endocrinology,the</i> , 2016 , 4, 560-2	18.1	14
28	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1580-90	27.4	307
27	SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. <i>Diabetologia</i> , 2016 , 59, 1333-1339	10.3	207
26	Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. <i>JAMA Cardiology</i> , 2016 , 1, 692-9	16.2	168

25	The new pooled cohort equations risk calculator. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 613-9	3.8	52
24	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 116-24	18.1	131
23	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. <i>Diabetologia</i> , 2014 , 57, 2513-20	10.3	22
22	The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. <i>Atherosclerosis</i> , 2014 , 237, 287-300	3.1	44
21	Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 1265-8	6.7	2
20	Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2012 , 14, 909-15	12.3	48
19	HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. <i>Diabetologia</i> , 2012 , 55, 1564-7	10.3	15
18	The case for diabetes screening: ADDITION-Europe. <i>Lancet, The</i> , 2011 , 378, 106-8	40	2
17	Statins and the risk of new-onset diabetes: a review of recent evidence. <i>Current Opinion in Lipidology</i> , 2011 , 22, 460-6	4.4	76
16	Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 2556-64	27.4	944
15	The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. <i>International Journal of Epidemiology</i> , 2011 , 40, 1530-8	7.8	46
14	Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. <i>European Heart Journal</i> , 2010 , 31, 1230-6	9.5	27
13	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet, The</i> , 2010 , 375, 735-42	40	1644
12	Statins and risk of incident diabetes [Authors' reply]. <i>Lancet, The</i> , 2010 , 375, 2141-2142	40	7
11	HbA1c: a useful cardiovascular risk marker in those without diabetes?. <i>Diabetologia</i> , 2010 , 53, 2468-9	10.3	1
10	Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. <i>Hepatology</i> , 2010 , 52, 1156-61	11.2	198
9	Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Diabetes Care</i> , 2009 , 32, 915-20	14.6	49
8	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. <i>Clinical Endocrinology</i> , 2009 , 70, 815-28	3.4	57

7	Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. <i>Clinical Endocrinology</i> , 2009 , 71, 456-457	3.4	0
6	Metabolic syndrome: collapsing under its own weight?. <i>Diabetic Medicine</i> , 2009 , 26, 457-9	3.5	6
5	Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2009 , 373, 1765-72	4.0	1015
4	Intensive glucose control and cardiovascular outcomes [Authors' reply]. <i>Lancet, The</i> , 2009 , 374, 524	4.0	
3	The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1337-43	2.9	28
2	Non-alcoholic fatty liver disease: what is it, when does it occur, and why does it matter?. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2007 , 24, 310-316		0
1	Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?. <i>International Journal of Clinical Practice</i> , 2007 , 61, 697-701	2.9	52